Search

Displaying results 1281 - 1290 of 9325 in total
  1. Drug

    Interferon alfa-2b

    go.drugbank.com/drugs/DB00105
    ApprovedInvestigational

    Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles i...

    Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)
  2. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … by preventing intramyometrial growths in the endometrial glands.

  3. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated. … The composition of PPFh should be 5% of protein from which 83% should consist of albumin and no more of 17% should be globulin.

  4. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    The global prevalence of obesity is increasing rapidly. … Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare.

  5. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47526] It is considered one of the most likely agents to be used in a biological attack. … around the world.

  6. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [A263481] Sotatercept was approved by the European Commission on August 26, 2024.[L51549] … It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.

  7. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357]. … Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.

  8. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. … monosaccharides which can be absorbed by the body.

  9. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.

  10. Drug

    Carmustine

    go.drugbank.com/drugs/DB00262
    ApprovedInvestigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). … It is used in the treatment of brain tumors and various other malignant neoplasms.

    Products: Bimustin 100 mg İnfüzyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 adet toz içeren flakon ve 1 adet çözücü flakon, BİCNU 100 MG ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON VE ÇÖZÜCÜSÜ, 1 ADET TOZ FLAKON, 1 ADET ÇÖZÜCÜ